FDA Oncology Announcements

Bcr-Abl inhibitor × Other × Clear all

10 Announcements

FDA Approves Ponatinib

Drug: Iclusig tablets (ponatinib) · Bcr-Abl inhibitor

Omacetaxine Mepesuccinate

Drug: SYNRIBO (omacetaxine mepesuccinate) · Bcr-Abl inhibitor

Bosutinib tablets

Drug: Bosulif (bosutinib) · Bcr-Abl inhibitor

Imatinib Mesylate Tablets

Drug: Gleevec (imatinib mesylate) · Bcr-Abl inhibitor

Dasatinib (Sprycel)

Drug: Sprycel (dasatinib) · Bcr-Abl inhibitor

Nilotinib (Tasigna)

Drug: Tasigna Capsules (nilotinib) · Bcr-Abl inhibitor

Imatinib Mesylate

Drugs: Gleevec (imatinib mesylate tablets for oral use) · Bcr-Abl inhibitor, Gleevec (oral use)

FDA Approves Dasatinib

Drug: Sprycel (dasatinib) · Bcr-Abl inhibitor

FDA Approves Nilotinib

Drug: Tasigna Capsules (nilotinib) · Bcr-Abl inhibitor

FDA approves imatinib mesylate (Gleevec) as a single agent for the treatment of multiple indications

Drug: Gleevec (imatinib mesylate) · Bcr-Abl inhibitor